1 terminated. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Terminated 1 |
Follow John Mark Sloan: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Idelalisib for Immunoglobulin M (IgM)-Associated Primary (AL) Amyloidosis Idelalisib - Amyloidosis | Phase 2 | Terminated | John Mark Sloan | 1 | 2016-01-01 | 2017-09-21 |
Amyloidosis (1)
idelalisib (1)
United States (1)